The expanded collaboration now also covers the generation of HuCAL-derived fully human antibodies for proteome research and target validation together with a renowned Japanese research organization as well as commercialization of resulting antibody products.
Under the terms of the agreement, GeneFrontier will utilize MorphoSys's HuCAL GOLD antibody library to generate HuCAL antibodies against targets provided by its collaboration partner. For this purpose, the HuCAL antibody technology was installed at GeneFrontier's research laboratories within a research facility in Tokyo.
GeneFrontier will provide MorphoSys with financial compensation for access to the HuCAL technology.
The companies said that they have agreed to share commercialization rights for all antibodies discovered in this project against targets identified and validated by GeneFrontier with its partner. Further financial details of the agreement were not disclosed.
"We are excited at this opportunity to expand our alliance with MorphoSys to apply the HuCAL technology to a number of our ongoing research programs with our partner," commented Makoto Ogasawara, President & CEO of GeneFrontier Corporation.
"This state-of-the-art technology will significantly accelerate the target validation process, and lead to the rapid discovery of novel therapeutics,” he said.